2. Academic Validation
  3. A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

  • Chem Commun (Camb). 2025 Jun 26;61(53):9693-9696. doi: 10.1039/d5cc01722j.
Qizhang Li 1,  Xing Lu 1,  Yuanli Yang 1,  Tianyu Li 2,  Xuehua Chen 1,  Rongmiao Yuan 1,  Xin Ding 2,  Silong Zhang 1,  Huan He 1
Affiliations

Affiliations

  • 1 Key Laboratory of Plant Resource Conservation and Germplasm Innovation in Mountainous Region (Ministry of Education), Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou University, Guiyang 550025, Guizhou Province, P. R. China. silongzhang@whu.edu.cn.
  • 2 Hubei Key Laboratory of Pollutant Analysis & Reuse Technology, Hubei Normal University, Huangshi 435002, P. R. China. dingx@hbnu.edu.cn.
PMID: 40468757 DOI: 10.1039/d5cc01722j
Abstract

Here we report PySAHA, a multifunctional HDAC Inhibitor, which can uniquely degrade HDACs within cells via a hydrophobic tagging mechanism, and also possesses photodynamic therapeutic activity. The synergistic interplay of these dual functionalities results in potent anti-breast Cancer efficacy.

Figures
Products